Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies-Reference-Cited by-同舟云学术

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Published:2013-01-02 Issue:1 Volume:27 Page:81-85
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Anta Lourdes,Llibre Josep M.,Poveda Eva,Blanco José L.,Álvarez Marta,Pérez-Elías María J.,Aguilera Antonio,Caballero Estrella,Soriano Vicente,de Mendoza Carmen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference12 articles.

1. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomized double-blind active-controlled trial.;Molina;Lancet,2011

2. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial.;Cohen;Lancet,2011

3. Rilpivirine: a next-generation nonnucleoside analogue for the treatment of HIV infection.;Fernandez-Montero;Expert Opin Pharmacother,2012

4. Update of the drug resistance mutations in HIV-1: December 2011.;Johnson;Top HIV Med,2011

5. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.;Rimsky;J Acquir Immune Defic Syndr,2012

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles;Journal of Medicinal Chemistry;2023-05-31

2. New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?;FEMS Microbiology Reviews;2022-09-20

3. APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants;Frontiers in Virology;2022-07-14

4. Pyridine/Pyrimidine Substituted Imidazol-5-one Analogs as HIV-1 RT Inhibitors: Design, Synthesis, Docking and Molecular Dynamic Simulation Studies;Current HIV Research;2021-12-22

5. Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials;Expert Opinion on Emerging Drugs;2021-07-01